Genetic Treatment for Blindness May Soon Be Possible
Topic: Disability Visual Aids
Author: American Academy of Ophthalmology - Contact: aao.org
Published: 2017/11/12
Contents: Summary - Introduction - Main Item - Related Topics
Synopsis: Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy.
Introduction
Study shows first-of-its-kind gene therapy can restore vision to people with an inherited retinal disorder.
Main Item
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented recently at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its-kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.
Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.
Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.
LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient's eyes.
Treatment doesn't restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.
More than 200 patients with LCA have participated in gene therapy trials since 2007. However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn't obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.
Explore Related Topics
1 - Tactile Lithophane Makes Scientific Data Accessible to Students With Blindness - Tactile learning device makes science accessible to students with blindness or low vision (BLV) opens possibility of transfer of scientific data or images for sighted students into functional formats for students with blindness.
2 - Scientists Identify Brain Region Where Individuals with Visual Impairments Recognize Faces through Sound - Using a specialized device that translates images into sound researchers showed that people who are blind recognized basic faces using the fusiform face area, a region of the brain that is crucial for the processing of faces in sighted people.
3 - Campus Maps for Students with Visual Impairments - SAS launches free resources to create and share non-visual digital maps to help open up the higher education experience.
4 - Acesight Electronic Glasses for Visually Impaired - Acesight electronic glasses use technology that assists people with severe low vision to regain visual independence.
5 - Flexible Artificial Retinas Use 2D Materials - The flexible artificial retina devices based on very thin 2D materials could someday restore sight to millions of people with retinal diseases.
Page Information, Citing and Disclaimer
Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.
Cite This Page (APA): American Academy of Ophthalmology. (2017, November 12). Genetic Treatment for Blindness May Soon Be Possible. Disabled World. Retrieved October 6, 2024 from www.disabled-world.com/assistivedevices/visual/lca.php
Permalink: <a href="https://www.disabled-world.com/assistivedevices/visual/lca.php">Genetic Treatment for Blindness May Soon Be Possible</a>: Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy.
Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.